TOP¡ä°å¶É¤Î¤´¾Ò²ð¡ä¶ÈÀÓ¾Ò²ð¡Ê2012ǯ¡Á2013ǯ¡Ë
¶ÈÀÓ¾Ò²ð
2013ǯ
¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð
- Asami T, Saito Y, Whitford TJ, Makris N, Niznikiewicz M, McCarley RW, Shenton ME, Kubicki M ; Abnormalities of middle longitudinal fascicle and disorganization in patients with schizophrenia.Schizophrenia research ; 143(2-3)253-259,2013
- Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T, ADMIRE Study Group ; Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study).Journal of affective disorders ; 151(3)899-905,2013
- Kato M, Nonen S, Serretti A, Tetsuo S, Takekita Y, Azuma J, Kinoshita T ; 5-HTTLPR rs25531A>G differentially influence paroxetine and fluvoxamine antidepressant efficacy:A randomized-controlled trial.Journal of clinical psychopharmacology ; 33(1)131-132,2013
- Kato M, Chang CM ; Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression.CNS drugs ; 27(S1)S11-S19,2013
- Komoto K, Ha-Kawa S, Tanigawa N, Kinoshita T ; Two Adult Cases of Pulmonary Artery Sling.Internal medicine ; 52(11)1271-1272,2013
- Nishida K, Morishima Y, Yoshimura M, Isotani T, Irisawa S, Jann K, Dierks T, Strik W, Kinoshita T, Koenig T ; EEG microstates associated with salience and frontoparietal networks in frontotemporal dementia, schizophrenia and Alzheimer's disease.Clinical neurophysiology ; 124(6)1106-1114,2013
- Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T ; A 12-week Randomized, Open-label Study of Perospirone Versus Aripiprazole in the Treatment of Japanese Schizophrenia Patients.Progress in neuro-psychopharmacology & biological psychiatry ; 40:110-114,2013
- ²ÃÆ£Àµ¼ù, ÌÚ¼ÉÒ»Ë, ÌÚ¼ µ£, ¸¶ µ±Ê¸ ; ¤¦¤ÄÉ¡¦¤¦¤Ä¾õÂ֤δµ¼Ô¤Ë¤ª¤±¤ëParoxetine±ö»À±ö¿åÏÂʪ½üÊü¾û(¥Ñ¥¥·¥ë®CR¾û)¤Ë´Ø¤¹¤ë°ÂÁ´À¤È͸úÀ¤Îɾ²Á¡Á¤¦¤ÄÉ¡¦¤¦¤Ä¾õÂ֤δµ¼Ô¤ËÂФ¹¤ë»ÈÍÑÀ®ÀÓÄ´ºº¤ÎÃæ´ÖÊó¹ð¡Á.ÌôÍý¤È¼£ÎÅ ; 41(8)749-764,2013
- Ë̱ºÍ´°ì, µÈ¼¶©»Ë, ¿¥ÅÄ͵¹Ô, ¹âÀ¥¾¡¶µ, ÌÚ²¼Íøɧ ; ¹ðÃΤòµñÈݤ·¤¿Î¾¿Æ¤È¾®»ù¤¬¤ó´µ¼Ô¤ÎÂбþ¤Ë¶ìθ¤·¤¿£±Îã.Àº¿À²Ê ; 22(2)233-238,2013
- Ë̱ºÍ´°ì, »°°æ ¹À, µÈ¼¶©»Ë, Pascual-Marqui RD, °ëë½ÓÌÀ, ÌÚ²¼Íøɧ ; ¤»¤óÌѤȤ¦¤ÄɤδÕÊ̤ËÆñ½Â¤·¤¿1Îã¤Ë¤ª¤±¤ëÄêÎÌǾÇȲòÀÏ.ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 14(1)59-63,2013
- ¶áÆ£Âç»°¡¤¾®Åĸ¶½ÓÀ®¡¤°ÀÅļç°ì¡¤ÃÓ¿¬µÁδ¡¤²¼ÅÄ·ò¸ã¡¤¹â¶¶ ¾½¡¤ÃÝÆâʸ°ì¡¤Ä¹Ã«ÀîÄ«Ê桤ƣ¸¶½¤°ìϺ¡¤µÈÅľ﹧¡¤µÈ¼¶©»Ë¡¤ÅĻҵ×É× ; ÆüËÜÁí¹çɱ¡Àº¿À°å³Ø²ñ²ñ°÷¤ËÂФ¹¤ëǧÃξɿÇÎŤ˴ؤ¹¤ë¥¢¥ó¥±¡¼¥ÈÄ´ºº.Áí¹çɱ¡Àº¿À°å³Ø ; 25(2)171-177,2013
- ÖÖË̲µ± ; Åý¹ç¼ºÄ´¾É¤ËÂФ¹¤ëperospirone¤Èaripiprazole¤Î̵ºî°Ù³äÉÕÈæ³Ó»î¸³ Î×¾²¸ú²Ì¤ÈǦÍÆÀ¤òÃæ¿´¤Ë.Î×¾²Àº¿ÀÌôÍý ; 16(1)136-139,2013
- µÈ¼¶©»Ë, À¾ÅÄ·½°ìϺ, ÖÖË̲µ±, ¹âÌî¸ç»Ë, »°°æ ¹À, Ë̱ºÍ´°ì, ²ÃÆ£Àµ¼ù, °ëë½ÓÌÀ, Pascual-Marqui RD, ÌÚ²¼Íøɧ ; ¸þÀº¿ÀÌô¤ÎÌôʪǾÇÈŪ¸¡Æ¤ sLORETA¤ÎÀµ¾ï¥Ç¡¼¥¿¥Ù¡¼¥¹¤è¤ë¹³Àº¿ÀÉÂÌô¤Î¾¯¿ôÎãͽÈ÷Ū¸¡Æ¤.ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 14(1)45-49,2013
- µÈÌî¿¿µª, ²¬Â¼¹¨Èþ, ÌðÌî͵»Ò, ÃæÊ¿¶Ç»Ò, »³ËÜÆØ»Ò, ¿ù»³Í´É×, ¼¾åµ®±É, ¹âÌî È», µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; Éü¿¦º¤Æñ¤Ê¿À·Ð¾É¤ª¤è¤Ó¤¦¤ÄÉ´µ¼Ô¤Î¿´ÍýŪÆÃħ¡Á¤¦¤ÄÉÂ¥ê¥ï¡¼¥¯¥Ç¥¤¥±¥¢Ä̽ê¼Ô¤Î¿´Íý¸¡ºº¤«¤é¡Á.(ºâ)¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬ËܵǰºâÃĸ¦µæ½õÀ®Êó¹ð½¸ ; (24)97-102,2013
Ãø½ñ
- Okugawa G ; Cerebellum and schizophrenia -The cerebellum volume reduction theory of schizophrenia.Handbook of the cerebellum and cerebellar disorder ; (4)1907-1921 Springer New York,2013
- ¥Õ¥¡¥ó¥Ç¥ó¥Ü¥¹(´Æ½¤), ÈËËñ»»ÃË, »ÍËÜ͵»Ò(´ÆÌõ), ²¬Â¼¹¨Èþ¤Û¤«(ËÝÌõ¶¨ÎÏ) ; APA¿´Íý³ØÂç¼Åµ ; 1-1056ÇÝÉ÷´Û,2013
- ´ä´Öµª»Ò, ¿¥ÅÄ͵¹Ô, ´ß¾å·Ã»Ò, Ë̸ýͳ´õ, 𱩠ÆÆ, ×¢¾ï½¨¿Í, Ê¡ÅĤä¤È¤ß, ʡ¼ÏÂÈþ, Ëܲ°ÉßÈþÆà, »³ÅÄÈÞº»»Ò, ÏÂÅľÈÊ¿ ; µßÌ¿µßµÞ¥»¥ó¥¿¡¼¤Ë¤ª¤±¤ë¼«»¦Ì¤¿ë¼Ô»Ù±çQ&A½¸¡ÁÆþ±¡½é´ü¤«¤é»Ï¤Þ¤ë¥½¡¼¥·¥ã¥ë¥ï¡¼¥¯¡Á ; 1-107ÂçºåÉܼ«»¦Ì¤¿ë¼ÔÏ¢·È»Ù±ç»ö¶ÈôÅö¼Ô²ñµÄÊÔ,2013
- ²ÃÆ£Àµ¼ù ; µ.³°Íè¤Î¥¬¥¤¥É¥é¥¤¥ó¿ÇÎÅ¡Á¿ÇÃÇ¡¦´ÉÍý¡¦¼£ÎÅ¡Á Àº¿À¡¦¿´¿È°å³Ø¼À´µ 45¤¦¤ÄÉÂ.º£Æü¤Î¿ÇÎŤΤ¿¤á¤Ë ¥¬¥¤¥É¥é¥¤¥ó³°Íè¿ÇÎÅ2013 ; 394-402Æü·Ð¥á¥Ç¥£¥«¥ë³«È¯,2013
- ²ÃÆ£Àµ¼ù ; º.¤è¤¯¤ß¤é¤ì¤ëÀº¿À¼À´µ ÁжËÀ¾ã³².¿À·Ð¡¦Àº¿À¼À´µ¼£Îťޥ˥奢¥ë ; ÆÃÊÌ(2)287-288ÆüËÜ°å»Õ²ñ,2013
- ÖÖË̲µ±, ²ÃÆ£Àµ¼ù ; Âè10¾Ï ¹³Àº¿ÀÉÂÌôÁªÂò¤Î¥¨¥Ó¥Ç¥ó¥¹.¹³Àº¿ÀÉÂÌô¥×¥é¥¯¥Æ¥£¥«¥ë¥¬¥¤¥É ; 122-135Ãæ³°°å³Ø¼Ò,2013
2012ǯ
¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð
- Kato M, Nonen S, Serretti, A., Tetsuo S, Takekita Y, Azuma J,
Kinoshita T. 5-HTTLPR rs25531A>G differentially influence paroxetine and
fluvoxamine antidepressant efficacy: A randomized-controlled trial. Journal
of Clinical Psychopharmacology 2012 Dec 28. [Epub ahead of print]
- Cardena E, Lehmann D, Faber PL, Jonsson P, Milz P, Roberto D. Pascual-Marqui ; EEG sLORETA FUNCTIONAL IMAGING DURING HYPNOTIC ARM LEVITATION AND VOLUNTARY ARM LIFTING. International Journal of Clinical and Experimental Hypnosis ; 60(1)31-53,2012
- Faber PL, Lehmann D, Tei S, Tsujiuchi T, Kumano H, Roberto D. Pascual-Marqui ; EEG source imaging during two Qigong meditations. Cognitive Processing ; 13(3)255-265,2012
- Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, Kato M, Wakeno M, Okugawa G, Kinoshita T, Kurosawa T, Hasegawa R, Saito Y ; Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry research ; 198(3)424-429,2012
- Lehmann D, Faber PL, Tei S, Roberto D. Pascual-Marqui, Milz P, Kochi K ; Reduced functional connectivity between cortical sources in five meditation traditions detected with lagged coherence using EEG tomography. Neuroimage ; 60(2)1574-1586,2012
- Sandmann P, Dillier N, Eichele T, Meyer M, Kegel A, Roberto D. Pascual-Marqui ; Visual activation of auditory cortex reflects maladaptive plasticity in cochlear implant users. Brain ; 135:555-568,2012
- Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T ; A 12-week Randomized, Open-label Study of Perospirone Versus Aripiprazole in the Treatment of Japanese Schizophrenia Patients. Progress in neuro-psychopharmacology & biological psychiatry ; 40:110-114,2012
- ÈÄÅ침¼ù, ¿ùËÜãºÈ, ÌÚ²¼Íøɧ ; ¡Ú¶µßµÞ³°Íè¤ÇÁø¶ø¤¹¤ëÀº¿À¾É¾õ¡¦Àº¿À¾ã³²¡ÛQ8 ºª¿ç¾õÂ֤Ȥ﨤ì¹þ¤ß¤ÇÈÂÁ÷¤µ¤ì¤¿¶ÛÄ¥ÉÂÀºªÌ¤δµ¼Ô¤Ø¤ÎÂбþ. µßµÞŽ¥½¸Ãæ¼£ÎÅ ; 24(1-2)50-55,2012
- Æ£°æ¹¯ÃË, ´äÅÄÃçÀ¸, ¹â¶¶À¶µ×, Àж¿²¬½ã, °ËÆ£½ç°ìϺ, °ËЮ²í¿Ã, Âçµ×ÊÝÁ±Ï¯, Â翹ůϺ, ÈøºêµªÉ×, ÌÚ²¼Íøɧ, ¾®»³ »Ê, ÎëÌÚƻͺ, Ãæ¹þϹ¬, Ãæ¼ ½ã, 𱩿¿°ì, Èõ¸ýµ±É§, Ê¿°ÂÎÉͺ, ¿åÌî²íʸ ; Àº¿À²Ê°å¤Î¥Ç¥ÝºÞ¤Ø¤Î¹½¤¨¡¢¼£Îžõ¶·¤Ë¤Ä¤¤¤Æ¤ÎÂ絬ÌÏ¥¢¥ó¥±¡¼¥ÈÄ´ºº¡ÁÆüÆÈÈæ³Ó·ë²Ì¤òÃæ¿´¤Ë¡Á. Î×¾²Àº¿ÀÌôÍý ; 15(5)797-810,2012
- ´äÅÄÃçÀ¸, Æ£°æ¹¯ÃË, ϵ¤Íµ»Ö, ¹â¶¶À¶µ×, Àж¿²¬½ã, °ËÆ£½ç°ìϺ, °ËЮ²í¿Ã, Âçµ×ÊÝÁ±Ï¯, Â翹ůϺ, ÈøºêµªÉ×, ÌÚ²¼Íøɧ, ¾®»³ »Ê, ÎëÌÚƻͺ, Ãæ¹þϹ¬, Ãæ¼ ½ã, 𱩿¿°ì, Èõ¸ýµ±É§, Ê¿°ÂÎÉͺ, ¿åÌî²íʸ ; ËÜË®¤Ë¤ª¤±¤ëÅý¹ç¼ºÄ´¾É¤ÎºÆȯͽËɤ˴ؤ¹¤ëǧ¼±¤È¼èÁȤߤμÂÂÖ¡ÁÅý¹ç¼ºÄ´¾ÉºÆȯͽËɸ¦µæ²ñ¥¢¥ó¥±¡¼¥ÈÄ´ºº512̾¤Î·ë²Ì¤è¤ê¡Á. Î×¾²Àº¿ÀÌôÍý ; 15(5)785-796,2012
- ÊÒ¾åůÌé, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; Remission, recovery¤òÌܻؤ¹¼£ÎŤˤª¤±¤ëaripiprazole¤Î͸úÀ¡ÁÅý¹ç¼ºÄ´¾É5¾ÉÎã¤ÎÎ×¾²Åª¸¡Æ¤¡Á. Î×¾²Àº¿ÀÌôÍý ; 15(1)85-91,2012
- Áýß·½¡ÍÎ, Åĸý¿Î»Î, ¿ùËÜãºÈ, ¾®ÅçÇîÇ·, ¾¾ËÜÁáÉÄ, ¾®Å縦ÂÀϺ, ¿·µÜ ¶½ ; áÖÄË¥³¥ó¥È¥í¡¼¥ë¤¬º¤Æñ¤Ç¤¢¤Ã¤¿½Ñ¸å¿À·Ð¾ã³²ÀáÖÄˤ˥ߥ륿¥¶¥Ô¥ó¤¬Í¸ú¤Ç¤¢¤Ã¤¿1¾ÉÎã. Ëã¿ì ; 61(9)1003-1005,2012
- ÖÖË̲µ±, ÅĶᰡÍö, Æ£»³²íÀ², À¾ÅÄ·½°ìϺ, ¿ùËÜãºÈ, ²ÃÆ£Àµ¼ù, µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; Blonanserin¤¬ÁÕ¸ù¤·¤¿Tourette¾ã³²¤Î1Îã. Àº¿À²Ê¼£ÎÅ³Ø ; 27(1)109-113,2012
- ÖÖË̲µ±, ºä°æ»ÖÈÁ, ¼ÅÄÃι¯, ¿¥ÅÄ͵¹Ô, ÅĶᰡÍö, µÈ¼¶©»Ë, ²ÃÆ£Àµ¼ù, ÌÚ²¼Íøɧ ; Âç³Øɱ¡³°Íè¤Ë¤ª¤±¤ërisperidoneÆøúÀÃí¼ÍÀ½ºÞ¤Î»ÈÍѷи³¡ÁËýÀ´üÅý¹ç¼ºÄ´¾É¤ª¤è¤Ó¼ºÄ´´¶¾ð¾ã³²´µ¼Ô57Îã¤ËÂФ¹¤ë6¥«·î´Ö¤ÎÎ×¾²Åª¸¡Æ¤¡Á. Áí¹çɱ¡Àº¿À°å³Ø ; 23(3)287-294,2012
- ÅÏîµÍ³²Â, ÅÄÃ潨ÌÀ, Roberto D. Pascual-Marqui, Ê¿ÅŬ°ì ; ¥ª¥É¥Ü¡¼¥ë²ÝÂê¤òÍѤ¤¤¿ÊÒƬÄË´µ¼Ô¤Î¿ë¹Ôµ¡Ç½É¾²Á. ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 13(1)37-42,2012
- »³ºêµ×Èþ»Ò, µÈÌî¿¿µª, ÌÚ²¼Íøɧ, ¾®Ìî½ãÊ¿ ; Âç³ØÀ¸¤Ë¤ª¤±¤ëÂпͶ²ÉÝŪ¿´À¡¢¤Õ¤ì¤¢¤¤¶²ÉÝŪ¿´À¤Èξ¿Æ¤ÎÍÜ°éÂÖÅ٤ˤĤ¤¤Æ. ¿´ÍýÎ×¾²³Ø¸¦µæ ; 29(6)673-682,2012
- µÈÌî¿¿µª, ÎëÌÚÊþ»Ò, ËÙÆâËãÈþ, ÌÚ²¼Íøɧ ; »ùƸ»×½Õ´ü¤Î¿À·Ð¾É´µ¼Ô¤Ë¤ª¤±¤ëû´ü¿´ÍýÎÅË¡¡Á´ü´Ö¡¦²ó¿ô¸ÂÄꥻ¥Ã¥·¥ç¥ó¤Î»î¤ß¡Á. ¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬ËܵǰºâÃĸ¦µæ½õÀ®Êó¹ð½¸ ; (23)105-110,2012
Ãø½ñ
- ÀТʸ¿®, ÆâÅÄÍβð, ¿¥ÅÄ͵¹Ô, ÌÚ¸µ¹¯²ð, ¾®Ã«½Ó°ì, ³¤Ë¡¹¯Íµ, µÆÃϱɼ¡, °Èºî¹îÇ·, º´¡¹ÌÚ½ÕÌÀ, º´ÅÄÀ¯Î´, ¹â¶¶ÎÉÅö, ±Ê°æ ½ß, ±ÊÈø¸÷°ì, µ×Ëö¿°ì, ¸ÅÀºÈ, ´ÝÌÐ ·ò ; ED¿ÇÎÅ¥¬¥¤¥É¥é¥¤¥ó(2012ǯÈÇ) ; 1-110 ¥ê¥Ã¥Á¥Ò¥ë¥á¥Ç¥£¥«¥ë,2012
- ²ÃÆ£Àµ¼ù, µÈ¼¶©»Ë ; ¡Ú20.Àº¿À²ÊµßµÞ¡Û¿À·Ð¾É¾õ¤òȼ¤¦Àº¿À¾É¾õ. º£Æü¤ÎÀº¿À¼À´µ¼£ÎÅ»Ø¿Ë ; 826-830 °å³Ø½ñ±¡,2012
- ²ÃÆ£Àµ¼ù ; ¡Ú6.¥²¥Î¥à¡Û¤¦¤Äɼ£ÎÅÈ¿±þÀ¤òµ¬Äꤹ¤ëÍ×°ø¡¦°äÅÁ»Ò. µ¤Ê¬¾ã³²¤ÎÌôÍý¡¦À¸²½³Ø¡Á¤¦¤ÄɤÎǾÆâ¥á¥«¥Ë¥º¥à¸¦µæ:¿ÊÊâ¤ÈÄ©Àï¡Á ; 264-281 °åÌô¥¸¥ã¡¼¥Ê¥ë¼Ò,2012
- ²ÃÆ£Àµ¼ù ; ÌôʪÎÅË¡(2)µ¤Ê¬Ä´À°Ìô. Àº¿À²Ê¼£ÎÅ³Ø µ¤Ê¬¾ã³²¤Î¼£ÎÅ¥¬¥¤¥É¥é¥¤¥ó ; 27(S)169-176 (³ô)À±Ï½ñŹ,2012
- »°°æ ¹À, µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; Ìôʪ¤ÈÃæÆÇ. Ǿ¤È¤³¤³¤í¤Î¥×¥é¥¤¥Þ¥ê¥±¥¢ 5.°Õ¼±¤È¿ç̲ ; 236-246 ¥·¥Ê¥¸¡¼,2012
- ¿ùËÜãºÈ, »³ÅÄÈÞº»»Ò, ÀÄú˱§°Ê, ÈÄÅ침¼ù, ¿¥ÅÄ͵¹Ô, ¹âÀ¥¾¡¶µ, ÅĶᰡÍö, ÌÚ²¼Íøɧ, ÃæëÔèÃË, ×¢¾ï½¨¿Í, ÏÂÅľÈÊ¿, º´Æ£ ÆÆ, ´ä´Öµª»Ò, ½»ÅĽïÍý°Í, Ìî¾åÃÒ»Ò, ¹â¶¶ÍµÈþ, Ë̳ÑÍλÒ, Ê¡ÅĤä¤È¤ß, ×¢ÌîÆóÈþ, ÂÀÅÄ͵»Ò, â°æËþ§, °æÇÈ͵ª»Ò, ±ä¸¶Ê¸½ï, Å£ÅÄ̯»Ò, ʡ¼ÏÂÈþ ; ÂçºåÉܼ«»¦Ì¤¿ë¼Ô¼ÂÂÖÄ´ººÊó¹ð½ñ ; 1-50 ÂçºåÉÜ/´ØÀ¾°å²ÊÂç³ØÁí¹ç°åÎÅ¥»¥ó¥¿¡¼,2012
- ¿ùËÜãºÈ, »³ÅÄÈÞº»»Ò ; °Õ¼±¾ã³²¤È´ÕÊ̤¬Æñ¤·¤¤Å¾´¹À¾ã³²¤Î»öÎã(¤¤¤ï¤æ¤ë¥Ò¥¹¥Æ¥ê¡¼¤Î»öÎã)¡Áº£¸å¤ÎÀººº¡¦¼£ÎŤؤĤʤ°¤¿¤á¤ÎÊýά¡Á. µßµÞ°åÎŤˤª¤±¤ëÀº¿À¾É¾õɾ²Á¤È½é´ü¿ÇÎÅ £Ð£Å£ÅC¥¬¥¤¥É¥Ö¥Ã¥¯ ; 173-182 ¤Ø¤ë¤¹½ÐÈÇ,2012
- ÅĶᰡÍö, ÌÚ²¼Íøɧ ; ¡Ú12.ÌôºÞÀ¡¦¾É¾õÀÀº¿À¾ã³²¡Û¹³É԰¡¦¿ç̲Ìô¤Ë¤è¤ëÀº¿À¾É¾õ. º£Æü¤ÎÀº¿À¼À´µ¼£ÎÅ»Ø¿Ë ; 455-458 °å³Ø½ñ±¡,2012